You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.
The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.
The Tampa Bay Times reports that an investigation into foreign ties is being launched following the departure of the CEO, a vice president, and four researchers from the Moffitt Cancer Center.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
While some groups have communicated their concerns directly to the agency, stakeholders have also formed a new coalition to publicly take issue with FDA's actions.
Pharmacogenetics and legal experts took particular issue with the agency's suggestion that "established" drug/gene relationships are found only in FDA-approved drug labels.
Speakers at the Association for Biomolecular Resource Facilities annual meeting gave advice on preparing for and recovering from hurricanes.
Spun out of Moffitt Cancer Center, M2Gen and the Total Cancer Care protocols promise rapid advancements in precision medicine, starting with oncology.
Publishing house Hearst is pushing into precision medicine with a $75 million investment in M2Gen, the informatics subsidiary of Moffitt Cancer Center.
The OncoArray Consortium researchers also uncovered a new candidate susceptibility gene for low-grade and borderline serous epithelial ovarian cancer.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.